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Abstract: Overactive bladder (OAB) is a prevalent condition which has an adverse effect on 
quality of life. The presence of urgency incontinence confers signiﬁ  cant morbidity above and 
beyond that of OAB sufferers who are continent. The primary treatment for OAB and urgency 
incontinence is a combination of behavioral measures and antimuscarinic drug therapy. The 
ideal antimuscarinic agent should effectively relieve the symptoms of OAB, with the minimum 
of side effects; it should be available as a once-daily sustained release formulation and in dos-
age strength that allows easy dose titration for the majority of sufferers. Solifenacin succinate 
was launched in 2005, and has been shown in both short and long term clinical trials to fulﬁ  ll 
these requirements. Solifenacin is a competitive M3 receptor antagonist with a long half-life 
(45–68 hours). It is available in two dosage strengths namely a 5 or 10 mg once-daily tablet. 
The efﬁ  cacy and tolerability of solifenacin for the treatment of all symptoms of OAB has 
been evaluated in a number of large, placebo controlled, randomized trials. Long-term safety, 
efﬁ  cacy, tolerability and persistence with treatment have been established in an open label 40 
week continuation study.
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Introduction
Urinary incontinence has been deﬁ  ned by the International Continence Society as “the 
complaint of any involuntary leakage of urine” (Abrams et al 2000). The prevalence 
of urinary incontinence has been estimated as 13.1% in women and 5.4% in men in 
a recent population-based survey conducted across 5 countries (Irwin et al 2006). 
Overactive bladder (OAB) is a symptom complex characterized by urinary urgency, 
which in turn drives the symptoms of frequency and nocturia with or without urgency 
incontinence. Epidemiological studies (Irwin et al 2006) have estimated the prevalence 
of OAB to be 14%–16% after the age of 40 years and prevalence increases inexora-
bly with age for both men and women. It is estimated that one third of OAB patients 
have urgency incontinence. The presence of urgency incontinence confers signiﬁ  cant 
morbidity above and beyond that of OAB sufferers who are continent (Milsom et al 
2001; Stewart et al 2003).
The primary treatment for OAB and urgency incontinence is a combination of 
behavioral measures (including bladder retraining) and antimuscarinic drug therapy. 
Despite the proven efﬁ  cacy of these drugs for the relief of OAB symptoms, side effects 
impair tolerability and persistence with therapy, dosing regimens are not always simple, 
efﬁ  cacy has been questioned, formulary listed dosage strengths are not always optimal 
and their cost may be prohibitive.
The ideal antimuscarinic agent should effectively relieve the symptoms of OAB, 
with the minimum of side effects; it should be available as a once daily sustained 
release formulation and in dosage strength that allows easy dose titration for the 
majority of sufferers. Solifenacin succinate is a relatively new antimuscarinic which Therapeutics and Clinical Risk Management 2008:4(1) 118
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has been shown in both short and long term clinical trials to 
fulﬁ  ll these requirements (Chapple 2000).
The aim of this review is to describe the pharmacological 
properties, and clinical evidence for the use of solifenacin.
Pathology of overactive bladder
The etiology of OAB is multifactorial. Although a large 
proportion of cases are idiopathic, recognized contributing 
factors include lower urinary tract pathology (infection, 
calculi, and stones), neurological conditions (stroke, 
dementias, multiple sclerosis), systemic conditions (congestive 
heart failure, diabetes mellitus), functional and behavioral 
conditions (caffeine and alcohol consumption, mobility), and 
side effects of medication (Ouslander 2004).
Involuntary detrusor muscle contractions may be 
associated with OAB. Bladder contraction is mediated by 
acetylcholine; a peripheral neurotransmitter which acts on 
muscarinic receptors of the detrusor muscle. Of the ﬁ  ve known 
muscarinic receptor subtypes (M1–M5), M2 and M3 receptors 
are found in the bladder and M3 receptors appears to be the 
most important for bladder contractility. The true function of 
M2 receptors within the bladder is incompletely understood 
but it is thought that they may oppose sympathetically 
mediated smooth muscle relaxation or result in the activation 
of a non-speciﬁ  c cationic channel and activation of potassium 
channels (Hedge et al 1997, 1999). It is also thought that in 
certain disease states such as neurogenic bladder dysfunction 
the M2 receptors may become more important in mediating 
detrusor contractions (Braverman et al 1998).
Antimuscarinic agents
Older antimuscarinic agents such as oxybutynin are neither 
bladder nor muscarinic receptor subtype selective and are 
thus associated with greater generalized anticholinergic side 
effects. Commonly reported side effects of all antimuscarinic 
drugs include dry mouth, constipation, blurred vision, gastro-
esophageal reﬂ  ux, and cognitive impairment. Adverse events 
and multiple daily dosing regimens affect drug tolerability, 
compliance, and ultimately treatment efﬁ  cacy. A study in 
1997 examining the real world (as opposed to clinical trial) 
efﬁ  cacy of predominantly immediate release oxybutynin 
demonstrated a signiﬁ  cant impairment of treatment efﬁ  cacy 
due to antimuscarinic side effects. Many patients who felt 
the medication was effective were unable to tolerate side 
effects and consequently only 18% of patients remained on 
treatment at six months (Kelleher et al 1997a). The slow 
release preparation of oxybutynin has been shown to be as 
efﬁ  cacious as immediate release oxybutynin, however is 
associated with a much reduced side effect proﬁ  le. Controlled 
release preparations are associated with reduced peak serum 
drug and metabolite levels, which lead to a reduced incidence 
and severity of adverse events (Birns et al 1997).
Recently concern has arisen regarding the potential 
for signiﬁ  cant cognitive impairment of patients receiving 
antimuscarinic drugs which exert an effect on M1 receptors 
and which can cross the blood brain barrier. Kay et al (2006) 
have shown using name face recognition testing that at a 
dose of 20 mg once daily oxybutynin has an effect similar 
to that of 10–20 years of cognitive deterioration. This is of 
major importance amongst elderly patients who may already 
exhibit a degree of cognitive impairment and for whom OAB 
is most prevalent. It is clearly also important among this 
group of patients who are often on multiple other medica-
tions some of which have anticholinergic effects. Kay et al 
showed that darifenacin which is highly M3 selective and 
tolterodine which does not cross the blood brain barrier to any 
signiﬁ  cant degree do not affect cognitive function. It is likely 
that solifenacin will in similar studies for the same reasons 
have no effect on cognitive function, and to date cognitive 
impairment has not been reported with this drug in clinical 
trials or clinical practice (Kay et al 2006).
Since the voluntary withdrawal of terodiline from the 
market by Pharmacia in 1993 due to concerns regarding 
cardiac function, in particular the occurrence of Torsades 
de Pointes in susceptible individuals cardiac function assess-
ment has been an integral part of the safety proﬁ  le of these 
drugs. None of the currently prescribed antimuscarinics 
used for the treatment of OAB have proven adverse cardiac 
proﬁ  les despite vigorous testing (Monahan et al 1990).
Pharmacokinetics of solifenacin
In drug development solifenacin has been shown to have 
functional selectivity for the bladder over other organs in ani-
mal models. In vivo and in vitro studies have shown greater 
bladder selectivity over salivary gland tissue than tolterodine 
and oxybutynin. This relative bladder selectivity was the 
rationale for development of solifenacin in the treatment of 
OAB (Hatanaka et al 2003; Ohtake et al 2003).
Solifenacin is a competitive M3 receptor antagonist. 
Peak plasma levels are reached 3–8 hours following oral 
administration. Solifenacin has 98% plasma protein binding 
and is highly distributed to peripheral tissues. Solifenacin 
has 90% bioavailability and a long half-life of 45–68 hours. 
The major metabolite has been found to have similar binding 
proﬁ  le to muscarinic receptors as that of solifenacin but less 
potency (Hedge et al 1997).Therapeutics and Clinical Risk Management 2008:4(1) 119
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Other animal studies have shown that the metabolism of 
solifenacin is mediated by the liver enzyme CYP3A4 and 
major metabolites can be detected in the urine feces and bile 
(Onderwater 1999). Solifenacin at therapeutic dosage does not 
appear to inhibit liver cytochrome P450 isoenzymes and there-
fore is unlikely to cause pharmacokinetic drug-drug interac-
tions based on CYP dependent metabolism of co-administered 
drugs. Solifenacin is not licensed for use in pediatric or preg-
nant patients (Yamanouchi Pharma America 2004).
Clinical efﬁ  cacy
Solifenacin is available in 2 dosage strengths namely a 5 or 10 mg 
once-daily tablet which can be taken with or without food. 
Phase 3 studies demonstrated a dose-dependent effect in the 
relief of the common symptoms of OAB namely frequency, 
urgency, nocturia and urgency incontinence. Patients are nor-
mally commenced on 5 mg and titrated according to clinical 
need and personal preference to 10 mg after 4–6 weeks of 
treatment. In clinical trials approximately 50% of patients 
request the higher dose when offered the opportunity to do so 
(Haab et al 2005). Side effects are also dose dependent, and 
include dry mouth, constipation, and blurred vision.
It is important to remember that in the original 12-week 
phase 3 studies upon which initial efﬁ  cacy and tolerability 
data were described, patients were randomized without 
choice to either the 5 mg or 10 mg dosage. Ultimately from 
our present understanding of dose selection this would 
have resulted in 50% of patients receiving too high or too 
low a dosage for their requirements, and both efﬁ  cacy and 
tolerability would be inﬂ  uenced by this process. Ultimately in 
the 40-week extension study, patients were all recommenced 
on 5 mg solifenacin for the ﬁ  rst 4 weeks of open label 
treatment after completion of the original 12-week studies 
and 4 weeks thereafter offered the option of dose escalation. 
At this time 50% of patients increased their dosage with 
improvement in efﬁ  cacy without noticeable tolerability issues 
(Yamanouchi Pharma America 2004).
Clinical trials
There have been several large, randomized clinical trials 
evaluating the efﬁ  cacy, safety, tolerability, and persistence 
with solifenacin (Table 1). Each of these trials will be 
discussed.
Chapple et al (2004a) conducted a phase 2 study to 
evaluate the effective dose of solifenacin for the treatment 
of OAB. This was a multicenter, double blind, placebo and 
tolterodine controlled trial. Following a single blind 2-week 
placebo run in, patients were randomized to 4 weeks of either 
placebo, solifenacin (2.5 mg, 5 mg, 10 mg, or 20 mg doses) or 
twice-daily immediate-release tolterodine (2 mg). 265 patients 
were enrolled and 192 patients completed the study.
The primary outcome measure of the study was the 
change from baseline, in the mean number of voids per 
24 hours. Secondary outcome measures included the change 
in volume of urine voided per void, and the mean number 
of urgency and incontinence episodes per 24 hours. Quality 
of life changes were assessed using the 27 item Contilife 
questionnaire.
Results of the study showed a signiﬁ  cant reduction in 
the mean number of voids per 24 hours, and an increase in 
the mean volume voided per void in the study group taking 
5 mg, 10 mg, and 20 g of solifenacin, when compared with 
the placebo group. There was no statistically signiﬁ  cant 
reduction in voiding frequency, and volume voided per void 
in the tolterodine and 2.5 mg solifenacin treated patients 
compared with placebo (Figure 1).
The efﬁ  cacy and tolerability of solifenacin was found to 
be dose dependant, with the greatest reduction in frequency 
occurring with the 20 mg dose. Neither solifenacin nor 
tolterodine treated patients experienced a significant 
reduction in the number of urgency or incontinence episodes. 
Quality of life assessment using the Contilife questionnaire 
showed an improvement in 4 domains (daily life activities, 
emotional consequences, sexuality, and self-image) in the 
solifenacin treated patients, compared with improvement 
in the daily life activities domain in the tolterodine treated 
group, when compared with placebo.
Dry mouth and constipation were the most commonly 
reported adverse events. The incidence of dry mouth was 
greatest in the solifenacin 20 mg treated group (n = 14, 38%), 
followed by the tolterodine treated group (n = 9, 24%), and 
then the 5 and 10 mg dose treated groups (n = 5, 14% for 
both groups).
Patients taking 20 mg of solifenacin reported the high-
est incidence of adverse events, followed by those patients 
taking tolterodine. The lowest incidence of adverse events 
was reported by patients taking 2.5 and 5 mg solifenacin.
Fourteen patients (7%) discontinued from the study due 
to adverse events; 7 of these patients were in the 20 mg 
solifenacin-treated group (one subject dropped out during the 
placebo run-in period), 6 patients were in the 10 mg solifenacin 
group, and 1 patient was taking 5 mg of solifenacin.
There have been 4 phase 3 trials, a 1-year open label 
extension study and a solifenacin and tolterodine head-to-
head study assessing the safety and tolerability of solifenacin 
in patients with OAB.Therapeutics and Clinical Risk Management 2008:4(1) 120
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Two initial phase 3 clinical trials were designed to 
evaluate the efﬁ  cacy and safety of 10 mg solifenacin in 
double blind, placebo-controlled trials (studies 013 and 
014). The primary endpoint for both studies was the change 
from baseline to 12 weeks in the number of micturitions in 
24 hours. The mean change in the number of incontinence 
episodes per 24 hours and mean volume voided per micturi-
tion, were used as secondary endpoints. Both studies showed 
solifenacin 10 mg to be superior to placebo in reducing 
micturition frequency, incontinence and urgency episodes, 
and the volume voided per micturition episode. There was 
no statistically signiﬁ  cant reduction in nocturia episodes in 
both studies. 1208 patients were recruited into the studies. 
Pharmacokinetic studies were performed before drug dosing, 
at steady state and post-dosing. Both studies reported mild 
to moderate adverse events, the most commonly reported 
being dry mouth and constipation. In study 013 there was 
one discontinuation due to dry mouth.
Cardozo et al (2004) conducted a 12-week, multicenter, 
randomized, double blind placebo controlled trial assessing 
the efﬁ  cacy of 5 and 10 mg doses of solifenacin. Safety and 
tolerability of solifenacin were secondary study objectives. 
Patients were randomized to once daily doses of placebo, 
5 mg or 10 mg of solifenacin.
The primary endpoint for this 12-week trial was the mean 
change in micturition episodes in 24 hours. Changes from 
baseline in the mean umber of urgency, nocturia and inconti-
nence episodes, and the mean volume voided per void, were 
used as secondary endpoints. 907 patients took part in the 
trial, and data from 857 patients was analyzed. 281 patients 
received placebo, 286 received 5 mg solifenacin and placebo, 
and 290 received 10 mg of solifenacin.
The mean reductions in the number of micturition, 
urgency, and nocturia episodes in 24 hours are shown in 
Figure 2. The reductions in urinary frequency and urgency 
episodes with solifenacin treatment were statistically signiﬁ  -
cant for both doses of solifenacin. One of the major ﬁ  ndings 
of this study was the signiﬁ  cant reduction in nocturia episodes 
in patients taking a 10 mg dose of solifenacin.
Half of the patients who were incontinent at baseline 
and received treatment with solifenacin (5 mg and 10 mg) 
were dry at the end of the study period. Rates of dry mouth 
were 7.7%, 23%, and 2.3% for solifenacin 5 mg, 10 mg and 
placebo respectively. 29 patients (3.2%) withdrew from 
Figure 1  Changes in bladder diary variables in a phase 2, solifenacin dose ﬁ  nding study.
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the study due to adverse events; this was greatest in the 
solifenacin 10 mg treated group (n = 12, 3.9%), then the 
placebo group (n = 10, 3.3%). Seven patients (2.3%) in the 
5 mg solifenacin-treated group withdrew from the study due 
to adverse events.
A 12-week phase 3a study assessing the efﬁ  cacy of 
5 mg and 10 mg solifenacin was conducted in a multicenter, 
double-blind, placebo-controlled trial, using 2 mg of imme-
diate release tolterodine as an active comparator (Chapple 
et al 2004b). The primary aim was to assess the efﬁ  cacy of 
solifenacin 5 and 10 mg whilst the secondary aims were to 
compare the safety and efﬁ  cacy with that of 2 mg immediate 
release (IR) tolterodine. After a 2-week placebo run-in period, 
subjects were randomized to either 2 mg IR tolterodine twice 
daily, placebo, solifenacin 5 mg or 10 mg. Baseline to end 
of study changes in the mean number of urgency, mixed 
incontinence and urgency incontinence episodes were used 
as study outcome measures. In addition, the mean number of 
voids per 24 hours and mean volume voided per void were 
also assessed.
1077 men and women received one of the study drugs. 
Results of the study showed a statistically signiﬁ  cant reduc-
tion in the number of urgency and urgency incontinence 
episodes in the patients receiving solifenacin, when compared 
with placebo. These changes were not statistically signiﬁ  cant 
in the tolterodine-treated group when compared with placebo. 
There was a signiﬁ  cant reduction in urinary frequency with 
all active treatments, this effect being greatest in the solifena-
cin 10 mg, and then the 5 mg group. There was a statistically 
signiﬁ  cant improvement in volume of urine per void in the 
solifenacin- and tolterodine-treated groups, when compared 
with placebo. The changes in study outcome measures are 
shown in Figure 3.
2.9% of participants (n = 31) withdrew from the study due 
to adverse events, with the highest rate of discontinuation in 
the placebo-treated group (n = 10, 3.7%). Five (1.9%) patients 
taking tolterodine and 16 patients taking solifenacin (n = 9, 
3.2% taking 5 mg dose, n = 7 taking 10 mg dose) withdrew 
from the study due to adverse events.
The incidence of dry mouth was 14%, 21.3%, and 18.6% 
in the 5 mg and 10 mg solifenacin- and tolterodine-treated 
patients respectively. Constipation was reported in a greater 
number of patients receiving solifenacin than tolterodine.
The study found the 5 and 10 mg doses of solifenacin to 
be more effective than placebo, in the treatment of OAB.
These preliminary studies lead to the STAR study; a head 
to head clinical trial comparing the efﬁ  cacy of the existing 
market leader tolterodine extended release with dose ﬂ  exible 
Figure 2  Reduction from baseline in the number of micturition and urgency episodes in 24 hours, and episodes of nocturia in patients receiving placebo, 5 mg, or 10 mg of 
solifenacin in a phase 3 trial (drawn from data of Cardozo et al 2004).
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solifenacin. This was a prospective, double blind, 2 arm, 
parallel group, 12-week study (Chapple et al 2005). 1200 
subjects were randomized, 593 were commenced on 5 mg 
solifenacin and 607 on 4 mg extended release tolterodine. 
The study design is described in Figure 4.
In this type of study the initial analysis is one of non-
inferiority of the test drug, and once established assessment of 
superiority may follow. The results of the study showed that 
solifenacin was not inferior to tolterodine in reducing the num-
ber of voids per 24 hours; 2.45 and 2.24 episodes, respectively. 
Solifenacin treatment resulted in a signiﬁ  cant improvement in 
urgency, nocturia, urge incontinence, and overall incontinence 
when compared with tolterodine. Reduction in pad usage was 
signiﬁ  cantly greater in the solifenacin-treated group than the 
tolterodine-treated group (1.72 and 1.19 respectively). Four 
weeks after treatment initiation, 48% of patients on solifenacin 
and 51% on tolterodine requested a dose increase.
The perception of bladder condition questionnaire 
(PBC) is a validated single-item questionnaire, which 
asks people to choose 1 of 6 responses describing the 
severity of their bladder condition. Assessment of the PBC 
questionnaire scores showed a greater improvement in the 
solifenacin-treated group than the tolterodine-treated group 
(1.51 and 1.33 respectively).
Adverse events were those associated with antimuscarinic 
therapy and were mild to moderate in severity.
The study concluded that the ﬂ  exible dosing of solif-
enacin is more effective in treating OAB compared with the 
highest licensed dose of extended release tolterodine.
The duration of most clinical trials is 12 weeks, owing, 
among other factors, to cost constraints, intensity of surveil-
lance, and the ethical considerations of long-term placebo 
treatment. Patients receive detailed follow up and incentives 
such as free study medication in order to complete the trial. 
Long term real world efﬁ  cacy and persistence with treatment 
cannot be easily extrapolated from short-clinical trials.
Participants in a 12-week study were offered a 40-week 
open label extension of solifenacin at both 5 and 10 mg doses. 
The aim of the study was to assess the long-term efﬁ  cacy 
and tolerability of solifenacin (Haab et al 2005). Participants 
were followed up at 3 intervals. Traditional outcome mea-
sures such as frequency, urgency, urgency incontinence, and 
nocturia episodes per 24-hour period and volume voided per 
void were used.
Figure 3  The percentage change from baseline in the mean number of urgency, incontinence, and urge incontinence episodes and mean voids in a 24-hour period (Drawn 
from data of Chapple et al 2004b).
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1633 patients took part in the study. 42% (685) of patients 
commenced and continued with a 5 mg dose of medication. 
6.6% (108) chose to increase the dose of study medica-
tion but subsequently went back to the lower dose. 51% of 
patients’ dose escalated and continued with the 10 mg dose of 
solifenacin. 81% of study participants completed the study.
Figure 5 shows the changes in bladder diary variables 
over the 1-year extension period. At the end of the study 
period, the mean number of incontinence and micturition 
episodes per 24 hours had decreased by 66% and 23%, 
respectively. 58% of patients who experienced more than one 
incontinence episode per day at the beginning of the study 
were continent at the conclusion of the trial.
4.7% of patients withdrew from treatment due to adverse 
events (0.4% withdrawals were due to dry mouth). Dry mouth 
was reported by 10% of patients on the 5 mg dose and 17% 
on the 10 mg dose of solifenacin. The overall reported rate of 
dry mouth was 21%. More than half of episodes of dry mouth, 
constipation and blurred vision were mild in severity.
At the end of the study, patients were asked about satis-
faction with treatment and tolerability, 85% were satisﬁ  ed, 
and 99% found tolerability of solifenacin to be satisfactory 
or acceptable.
The Kings health questionnaire (KHQ) (Kelleher et al 
1997b), a 10-domain quality of life instrument designed 
for the assessment of quality of life among patients with 
lower urinary tract dysfunction, was used in 2 of the phase 
3 studies (Chapple et al 2004b; Cardozo et al 2004) and the 
open label extension study. The domains of the KHQ assess 
general health perceptions, incontinence impact, role, social 
and physical limitations, personal relationships, sleep/energy, 
emotions, severity measures, and symptom severity. There 
are 34 linguistic validations of the KHQ and it has been 
used in many studies of drug therapy for OAB (Kelleher 
et al 2005).
Quality of life data analysis of a 12-week trial conducted 
by Chapple et al (2004b) showed a signiﬁ  cant improvement 
in 5 of the domains of the KHQ in patients taking 5 and 10 mg 
doses of solifenacin compared with placebo (role limita-
tions, physical limitations, emotions, severity measures, 
and symptom severity). Patients taking 10 mg of solifenacin 
also reported a signiﬁ  cantly greater score in the incontinence 
impact domain. Results from the phase 3 trial study by 
Cardozo et al (2004) also showed statistically signiﬁ  cant 
improvements in 5 domains of the KHQ for both doses of 
solifenacin compared to placebo (incontinence impact, role 
limitations, emotions, sleep/energy, and symptom severity). 
Patients taking the 10 mg dose of solifenacin also reported 
an improvement in the physical limitations and severity 
measures domains (Figure 6).
Quality of life data from the long term extension study 
showed a signiﬁ  cant improvement in 9 of the 10 domains of 
the KHQ (with the exception of the personal relationships 
domain). Almost two thirds of this improvement occurred 
in the ﬁ  rst 3 months of treatment and was sustained for 
the duration of the study. Analysis of these data showed a 
signiﬁ  cant improvement in all quality of life domains for 
patients treated with 5 and 10 mg of solifenacin, which 
were 17% for the general health perceptions domain, and 
35%–48% improvement in all other domains. Quality of life 
Figure 4  Design of the STAR study.
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Figure 5 Median percentage reductions in frequency, urgency, and nocturia in long-term solifenacin treated patients. Reprinted with permission from Haab F, Cardozo L, 
Chapple C, et al. 2005. Long term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol, 
47:376–84. Copyright © 2005 Elsevier. 
Figure 6  Pooled changes from baseline in the KHQ domains for 2 of the phase 3 trials for solifenacin.
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improvements continued throughout the 40-week extension 
period (Figure 7).
Previous studies of solifenacin have used changes in 
micturition frequency as the primary outcome measure 
of treatment effectiveness. Two recent trials have used 
urgency as the primary outcome variable. The Venus trial 
(Vesicare efﬁ  cacy and safety in patients with urgency study) 
investigated the efﬁ  cacy and safety of 5 and 10 mg doses of 
solifenacin using a novel outcome measure of urgency called 
warning time. Warning time is deﬁ  ned as “the time from the 
ﬁ  rst sensation of urgency to voluntary micturition or inconti-
nence” (Chalifoux 1980). Warning time was measured using 
a stopwatch for a 1-day period prior to study-related visits.
739 patients participated in the study, 372 received 
either 5 or 10 mg solifenacin, and 367 received placebo. The 
results of the study showed a signiﬁ  cant increase in warning 
time in patients receiving solifenacin, 186.4 seconds versus 
54.7 seconds in the placebo group. Qualitative measures of 
urgency were evaluated using the urgency perception scale 
(UPS); a validated three point scale and the Indevus urgency 
severity scale (IUSS); a single item patient reported measure 
of urgency severity (Toglia et al 2006a). Full data from this 
trial had not been published at the time of preparing of this 
manuscript. Previous clinical trials evaluating tolterodine and 
darifenacin have used warning time as an endpoint measure; 
however have failed to show a signiﬁ  cant increase in warning 
time (Toglia 2006b; Zinner et al 2006).
Cardozo et al (2003) have previously shown a signiﬁ  cant 
improvement in warning time for darifenacin compared to 
placebo in a randomized, double blind, placebo controlled 
study. The dose of darifenacin used was 30 mg, namely twice 
the maximal licensed dose for the treatment of OAB.
The 16-week Sunrise study (solifenacin in the treatment 
of urgency symptoms of OAB in a rising dose, randomized, 
placebo controlled, double blind, efﬁ  cacy trial) assessed the 
effects of 5 and 10 mg solifenacin on urgency severity and 
bother. The majority of clinical trials of OAB treatments use 
frequency and incontinence episodes as primary outcome 
variables as they are easy to objectively measure. Urgency is 
difﬁ  cult to measure but remains the deﬁ  ning and most bother-
some symptom of OAB and as such of greatest importance to 
patients and prescribers (Cardozo et al 2006a). All patients 
Figure 7  Changes from baseline in the KHQ domains for the open label solifenacin extension study.
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were offered dose escalation half way through the study, 
the dose of solifenacin dispensed was based on a second 
randomization, whereby patients taking 5 mg solifenacin had 
a 50% chance of receiving a 10 mg dose. Urgency severity 
and bother were chosen as the primary end points for the 
study. A validated 5-point urgency scale; the PIUS, and a 
visual analogue scale (VAS) assessing urgency bother were 
used. The perception of bladder condition (PBC) which is 
a validated, single item questionnaire, and a treatment sat-
isfaction visual analogue scale were also used. Traditional 
bladder diary measurements namely, frequency, urgency and 
incontinence episodes per 24 hours were used as secondary 
outcome variables.
503 patients received solifenacin, starting at 5 mg, 
which could be increased to 10 mg if required. 206 patients 
received placebo. Patients receiving solifenacin achieved a 
signiﬁ  cantly greater reduction in urgency, frequency, and 
urge incontinence episodes when compared with placebo. 
These trends were also reﬂ  ected in the qualitative measures. 
There was a 42.4% and 31.7% reduction in the urgency bother 
VAS and PBC scores respectively. Treatment satisfaction 
was signiﬁ  cantly increased.
The incidences of dry mouth and constipation were higher 
in patients receiving solifenacin (15.8% and 6.9% respec-
tively) than placebo (2.7% and 2.2% respectively). The rate 
of blurred vision was equivocal. Discontinuation rates for 
solifenacin and placebo were similar (12.1% and 11.6%) 
(Cardozo et al 2006b). Full data from this trial had not been 
published at the time of preparing this manuscript.
Conclusion
Solifenacin was launched in 2005 as the ﬁ  rst once-daily, 
ﬂ  exible-dose, M3-receptor-selective antimuscarinic for the 
treatment of OAB. The efﬁ  cacy and tolerability of solifenacin 
for the treatment of all symptoms of OAB has been evaluated 
in a number of large, placebo controlled, randomized trials. 
Long-term safety, efﬁ  cacy, tolerability, and persistence with 
treatment have been established in an open label 40-week 
continuation study. Studies have shown that 50% of patients 
select the higher and lower dose of solifenacin respectively in 
the clinical trial setting. Higher doses of solifenacin are not 
associated with higher rates of discontinuation. Solifenacin 
has been shown to improve patients’ perception of their 
bladder symptoms and the quality of life of OAB sufferers. 
In addition, recent studies utilizing an array of measures of 
urgency have shown that irrespective of the measure used 
urgency is improved by solifenacin. A large post-marketing 
head-to-head study comparing solifenacin ﬂ  exible dose and 
extended release tolterodine ﬁ  xed dose showed a signiﬁ  cant 
beneﬁ  t of solifenacin treatment.
In clinical practice, patients are commenced on 5 mg 
of solifenacin and offered dose titration at 4–6 weeks of 
treatment. This may enhance treatment efﬁ  cacy, and allow 
optimum control of OAB. Whether optimal dose titration in 
clinical practice mirrors that seen in clinical trials is yet to 
be established.
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